{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:42:34Z","timestamp":1793364154113,"version":"4.5.0"},"reference-count":61,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Hepatitis B virus (HBV) infection is a leading cause of chronic liver disease and liver cancer worldwide. Hepatocellular carcinoma (HCC) remains one of the major causes of cancer-related mortality globally. Effective prevention and management strategies for HBV infection are crucial in reducing liver-related complications, including HCC. HBV plays a distinct role in liver carcinogenesis, and there is growing knowledge about the factors contributing to its oncogenic potential. With advancements in HCC management, special attention must be given to the treatment of HBV infection in patients with HBV-induced HCC. In this review, we summarize current insights into the carcinogenic mechanisms of HBV and discuss the latest approaches to managing HBV-induced HCC.<\/jats:p>","DOI":"10.3390\/jcm14072505","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T10:06:28Z","timestamp":1744020388000},"page":"2505","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Hepatitis B-Induced Hepatocellular Carcinoma: Understanding Viral Carcinogenesis and Disease Management"],"prefix":"10.3390","volume":"14","author":[{"given":"Yasamin","family":"Farbod","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, McGill University, Montreal, QC H3A 0G4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husain","family":"Kankouni","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Moini","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, McMaster University, Hamilton, ON L8S 2A5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"ref_1","unstructured":"Rodrigo, L. (2021). Epidemiology of Hepatitis B Virus. Hepatitis B, IntechOpen."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","article-title":"Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: A systematic review","volume":"7","author":"Alberts","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jmv.1890220311","article-title":"Extension of the epidemiology of hepatitis B in circumpolar regions through a comprehensive serologic study in the Northwest Territories of Canada","volume":"22","author":"Larke","year":"1987","journal-title":"J. Med. Virol."},{"key":"ref_4","unstructured":"Center for Disease Control and Prevention (2025, February 01). Hepatitis B Surveillance, Available online: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2021surveillance\/hepatitis-b.htm."},{"key":"ref_5","unstructured":"World Health Organization (2025, February 01). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_6","unstructured":"Government of Canada (2025, February 01). Primary Care Management of Hepatitis B\u2014Quick Reference (HBV-QR), Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/reports-publications\/primary-care-management-hepatitis-b-quick-reference.html."},{"key":"ref_7","unstructured":"Government of Canada (2025, February 01). Hepatitis B Vaccines: Canadian Immunization Guide, Available online: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-7-hepatitis-b-vaccine.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: Update 2009","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e2222367","DOI":"10.1001\/jamanetworkopen.2022.22367","article-title":"Association of Nationwide Hepatitis B Vaccination and Antiviral Therapy Programs With End-Stage Liver Disease Burden in Taiwan","volume":"5","author":"Chiang","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101775","DOI":"10.1016\/j.canep.2020.101775","article-title":"Changing risk factors for hepatocellular carcinoma in hyperendemic regions in the era of universal hepatitis B vaccination","volume":"67","author":"Wang","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Qu, C., Chen, T., Fan, C., Zhan, Q., Wang, Y., Lu, J., Lu, L.L., Ni, Z., Huang, F., and Yao, H. (2014). Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: A cluster randomized controlled trial. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001774"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/hep.24442","article-title":"Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program","volume":"54","author":"McMahon","year":"2011","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"a021436","DOI":"10.1101\/cshperspect.a021436","article-title":"Hepatitis B virus genotypes and variants","volume":"5","author":"Lin","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1053\/gast.2003.50053","article-title":"Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers","volume":"124","author":"Kao","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/carcin\/bgh172","article-title":"Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: A case control study","volume":"25","author":"Yuen","year":"2004","journal-title":"Carcinogenesis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e70008","DOI":"10.1111\/jvh.70008","article-title":"Long-Term Outcome of Chronic Hepatitis B-Histological Score and Viral Genotype Are Important Predictors of Hepatocellular Carcinoma","volume":"32","author":"Eilard","year":"2025","journal-title":"J. Viral Hepat."},{"key":"ref_20","first-page":"101274","article-title":"PreS1 deletions in genotype C HBV leads to severe hepatic inflammation and hepatocarcinogenesis via the IRE1-JNK axis","volume":"7","author":"Choi","year":"2025","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Khan, M.N., Mao, B., Hu, J., Shi, M., Wang, S., Rehman, A.U., and Li, X. (2024). Tumor-associated macrophages and CD8+ T cells: Dual players in the pathogenesis of HBV-related HCC. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1472430"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/JHC.S307962","article-title":"The Mechanisms of HBV-Induced Hepatocellular Carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sivasudhan, E., Blake, N., Lu, Z., Meng, J., and Rong, R. (2022). Hepatitis B Viral Protein HBx and the Molecular Mechanisms Modulating the Hallmarks of Hepatocellular Carcinoma: A Comprehensive Review. Cells, 11.","DOI":"10.3390\/cells11040741"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e6835","DOI":"10.1097\/MD.0000000000006835","article-title":"The association between hepatitis B mutants and hepatocellular carcinoma: A meta-analysis","volume":"96","author":"Wei","year":"2017","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jhep.2014.04.041","article-title":"Hepatitis B virus PreS\/S gene variants: Pathobiology and clinical implications","volume":"61","author":"Pollicino","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.omtn.2020.08.014","article-title":"ROS\/NF-\u03baB Signaling Pathway-Mediated Transcriptional Activation of TRIM37 Promotes HBV-Associated Hepatic Fibrosis","volume":"22","author":"Xie","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.tranon.2018.02.015","article-title":"Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus","volume":"11","author":"Fridkin","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eaal2380","DOI":"10.1126\/science.aal2380","article-title":"Epigenetic plasticity and the hallmarks of cancer","volume":"357","author":"Flavahan","year":"2017","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.7150\/jca.33005","article-title":"Association between gene methylation and HBV infection in hepatocellular carcinoma: A meta-analysis","volume":"10","author":"Zhang","year":"2019","journal-title":"J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/15592294.2016.1151586","article-title":"Comparison of genome-scale DNA methylation profiles in hepatocellular carcinoma by viral status","volume":"11","author":"Song","year":"2016","journal-title":"Epigenetics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canlet.2010.09.018","article-title":"Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt\/\u03b2-catenin signaling","volume":"300","author":"Hsieh","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_34","first-page":"3453","article-title":"Hepatitis B Virus X Protein Modulates the Expression of PTEN by Inhibiting the Function of p53, a Transcriptional Activator in Liver Cells1","volume":"63","author":"Chung","year":"2003","journal-title":"Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.3748\/wjg.v16.i39.4932","article-title":"HBx-induced reactive oxygen species activates hepatocellular carcinogenesis via dysregulation of PTEN\/Akt pathway","volume":"16","author":"Ha","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/hep.31313","article-title":"HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC","volume":"73","author":"Kim","year":"2021","journal-title":"Hepatology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Cui, T., Wei, F., Zhou, Z., Sun, Y., Gao, C., Xu, X., and Zhang, H. (2024). Wnt\/\u03b2-Catenin signaling pathway in hepatocellular carcinoma: Pathogenic role and therapeutic target. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1367364"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-Year Study of the Course of Hepatitis \u0394 Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/jvi.68.2.1052-1058.1994","article-title":"Expression of the hepatitis delta virus large and small antigens in transgenic mice","volume":"68","author":"Guilhot","year":"1994","journal-title":"J. Virol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Maestro, S., G\u00f3mez-Echarte, N., Camps, G., Usai, C., Su\u00e1rez, L., Vales, \u00c1., Olag\u00fce, C., Aldabe, R., and Gonz\u00e1lez-Aseguinolaza, G. (2021). AAV-HDV: An Attractive Platform for the In Vivo Study of HDV Biology and the Mechanism of Disease Pathogenesis. Viruses, 13.","DOI":"10.20944\/preprints202103.0411.v1"},{"key":"ref_42","first-page":"100098","article-title":"TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection","volume":"2","author":"Usai","year":"2020","journal-title":"JHEP Rep. Innov. Hepatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10059-009-0100-5","article-title":"Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling","volume":"28","author":"Park","year":"2009","journal-title":"Mol. Cells"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lombardo, D., Franz\u00e8, M.S., Caminiti, G., and Pollicino, T. (2024). Hepatitis Delta Virus and Hepatocellular Carcinoma. Pathogens, 13.","DOI":"10.3390\/pathogens13050362"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40139-015-0093-z","article-title":"TNF\u03b1 in liver fibrosis","volume":"3","author":"Yang","year":"2015","journal-title":"Curr. Pathobiol. Rep."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrgastro.2012.114","article-title":"Hepatic stem cells and transforming growth factor \u03b2 in hepatocellular carcinoma","volume":"9","author":"Majumdar","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.26180","article-title":"Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection","volume":"58","author":"Hosaka","year":"2013","journal-title":"Hepatology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","article-title":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis","volume":"78","author":"Choi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/gutjnl-2012-302024","article-title":"Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis","volume":"62","author":"Zoutendijk","year":"2013","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhep.2024.03.019","article-title":"Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: The DELTA-HCC study","volume":"81","author":"Lamarque","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5114\/ceh.2018.78127","article-title":"Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence","volume":"4","author":"Simon","year":"2018","journal-title":"Clin. Exp. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jjco\/hyz046","article-title":"Effects of TACE and preventive antiviral therapy on HBV reactivation and subsequent hepatitis in hepatocellular carcinoma: A meta-analysis","volume":"49","author":"Zhang","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8864655","DOI":"10.1155\/2021\/8864655","article-title":"Hepatitis B Virus Reactivation Potential Risk Factors in Hepatocellular Carcinoma via Transcatheter Arterial Chemoembolization: A Retrospective Research","volume":"2021","author":"Wang","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.gande.2022.10.001","article-title":"Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus","volume":"1","author":"Wu","year":"2023","journal-title":"Gastroenterol. Endosc."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/jgh.12910","article-title":"Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib","volume":"30","author":"Xu","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1111\/jgh.13425","article-title":"Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib","volume":"31","author":"Zhang","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e001072","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","first-page":"5234969","article-title":"Evaluation of Antiviral Therapy Performed after Curative Therapy in Patients with HBV-Related Hepatocellular Carcinoma: An Updated Meta-Analysis","volume":"2016","author":"Yuan","year":"2016","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.3892\/mco.2015.614","article-title":"Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: A meta-analysis","volume":"3","author":"Zhang","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1200\/JCO.2012.48.5896","article-title":"Effect of antiviral treatment with nucleotide\/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study","volume":"31","author":"Yin","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2505\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:11:23Z","timestamp":1760029883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14072505"],"URL":"https:\/\/doi.org\/10.3390\/jcm14072505","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]}}}